Mega Pharma introduces Dengue Combo Kit to Sri lankan market
Mega Pharma (Pvt.) Ltd recently announced the newest product that entered the company’s portfolio, Access Bio’s Carestart Dengue Combo Kit, at a launch ceremony held at Waters Edge, with the participation of dignitaries from both organisations as well as local doctors and other distinguished invitees.
Founded in 2001 and headquartered in Somerset, New Jersey, the USA, Access Bio Inc. researches, develops, manufactures and sells in vitro rapid diagnostic tests, biosensors and molecular diagnostic products worldwide.
Dedicated to the prevention and early diagnosis of infectious diseases, Access Bio and its Korea-based sister company Wells Bio Inc., with its state-of-the-art research and development facility, manufacture over 120 million rapid diagnostic tests annually for the detection of a range of infectious diseases, including malaria, dengue and HIV.
The dengue virus is transmitted by mosquitoes and more than onethird of the world’s population is at risk for infection. Since there are no vaccines available to prevent infection with the dengue virus, early diagnosis and prompt supportive treatment can substantially lower the risk of medical complications and death. Wells Bio CEO Dr. Byoung Don Han elaborated that this particular product provides a qualitative rapid diagnostic test that can simultaneously detect dengue virus in all clinical stages using both dengue NS1 antigen and anti-dengue antibodies (IGM/IGG) with one device. It also provides a diagnosis of dengue infection from acute to convalescent stage and the detection of all four dengue serotypes from serum, plasma or whole blood, Dr. Byoung Don Han said. Speaking to Mirror Business at the launch ceremony of the Carestart Dengue Combo Kit, Mega Pharma (Pvt.) Ltd Chairman and Managing Director Shirantha Peries said, “The Mega Pharma Group of Companies has registered the Carestart Dengue Combo Kit, since it detects two parameters, that is the primary infection and the secondary infection at the same time. Therefore, the chances of missing dengue fever whether it’s primary, secondary or even mixed infection, is very remote and almost not possible but through that the amount of lives that will be saved in this country is our objective.”
Pending for two years on government approvals, the product was finally introduced and supplied to the private healthcare sector and will be introduced to the government sector along with the necessary approvals and certifications. It is advised that the product should be used by an expert to an individual and hence, has not yet been announced to the public for purchase.
The Carestart Dengue Combo Kit is priced at Rs.1,000 for doctors and Rs.1,500 for tests.
Mega Pharma (Pvt.) Ltd was incorporated in 1995 as a Private Limited Liability Company and typically imports and markets high-quality pharmaceuticals from around the globe. As a leading marketer, Mega Pharma has grown to become a progressive specialised pharmaceutical company engaged in promoting prescription pharmaceutical products and high-tech medical devices.